8-K: Stryker Reports Strong Q2 2026 Results, Recovers from Cyber Incident

Stryker Corporation announced robust second quarter 2026 financial results, with net sales up 9.4% and EPS soaring 44.1%, signaling a strong recovery post-cyber incident.

Summary

• Stryker Corporation reported strong second quarter 2026 results, with net sales increasing by 9.4% to $6.6 billion and organic net sales growing by 9.0%.
• Reported earnings per share (EPS) saw a significant increase of 44.1% to $3.30, while adjusted EPS rose 17.9% to $3.69.
• The MedSurg and Neurotechnology segment reported net sales growth of 9.7%, with organic net sales up 9.2%, driven by unit volume.
• The Orthopaedics segment also showed solid performance with net sales up 9.1% and organic net sales increasing by 8.6%, primarily due to higher unit volume.
• The company is narrowing its full-year 2026 outlook, now expecting organic net sales growth between 8.3% and 9.3%, and adjusted EPS between $14.95 and $15.10.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong financial performance, effective recovery from a cyber incident, and confident management commentary indicating robust underlying business momentum.

Positives

• Reported net sales increased 9.4% to $6.6 billion in the second quarter of 2026.
• Organic net sales increased by 9.0% in the second quarter, driven by unit volume.
• Reported EPS increased by 44.1% to $3.30.
• Adjusted EPS increased by 17.9% to $3.69.
• MedSurg and Neurotechnology segment organic net sales grew 9.2%, with 9.1% from unit volume.
• Orthopaedics segment organic net sales grew 8.6%, driven by unit volume.
• The company is recovering well from a prior cyber incident, as noted by the CEO.
• Confidence in growing at the high end of the MedTech industry.

Negatives

• The company reported goodwill and other impairments of $1 million in Q2 2026, compared to $55 million in Q2 2025.
• Reported gross profit margin was 68.3% in Q2 2026, a decrease from 63.8% in Q2 2025, though adjusted gross profit margin improved.
• Reported operating income margin was 25.2% in Q2 2026, an increase from 18.5% in Q2 2025, but adjusted operating income margin saw a larger increase.
• The company is narrowing its full-year 2026 guidance, which could indicate some uncertainty despite strong Q2 performance.

Risks

• Weakening economic conditions or the anticipation thereof could adversely affect demand for products.
• Geopolitical risks, including tariffs and international conflicts, could lead to increased market volatility.
• Pricing pressures and cost-containment measures could adversely affect product prices or demand.
• Changes in foreign currency exchange markets pose a risk.
• Unanticipated issues in clinical studies or regulatory approvals from agencies like the FDA.
• Inflationary pressures and increased interest rates or volatility.
• Supply chain disruptions and changes in labor markets.
• Cybersecurity risks, including breaches, failures, or disruptions of IT systems, referencing the incident on March 11, 2026.

Future Outlook

The company is narrowing its full-year 2026 guidance, now expecting organic net sales growth in the range of 8.3% to 9.3% and adjusted net earnings per diluted share in the range of $14.95 to $15.10. This guidance includes a modestly positive pricing impact and a slightly favorable foreign exchange impact.

Management Comments

• "We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter," said Kevin A. Lobo, Chair and CEO.
• "As we have seen in the past, the resilience of our teams when faced with challenges was once again on display."
• "With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech."

Industry Context

StockSavvy.ai notes that Stryker's strong Q2 2026 performance, particularly its recovery from a cyber incident and robust sales growth across its key segments, positions it well within the competitive MedTech landscape. The company's focus on innovation and operational execution aligns with industry trends favoring companies that can navigate supply chain challenges and regulatory environments effectively.

Comparison to Industry Standards

• Stryker's reported net sales growth of 9.4% in Q2 2026 exceeds the typical growth rates seen in the broader medical device industry, which often hovers in the mid-single digits.
• The company's adjusted EPS growth of 17.9% demonstrates strong operational leverage and profitability, outperforming many peers who may be experiencing margin pressures.
• The organic net sales growth of 9.0% indicates robust underlying demand for Stryker's products, a positive sign compared to industry benchmarks that might be affected by economic slowdowns.
• While specific competitor data is not provided in this filing, Stryker's ability to achieve these growth figures post-cyber incident suggests superior operational resilience compared to companies that have faced similar disruptions.

Legal Proceedings

• The company mentions 'regulatory and legal matters' as an item excluded from adjusted earnings, indicating ongoing or past legal and regulatory issues.

Stakeholder Impact

• Shareholders: Positive impact due to strong reported and adjusted EPS growth, and a narrowed positive full-year outlook.
• Employees: Positive impact from management's acknowledgment of team resilience and confidence in future growth.
• Customers: Continued access to innovative products and services in MedSurg, Neurotechnology, and Orthopaedics.
• Suppliers: Continued business relationship with a growing company, though subject to potential supply chain risks mentioned.

Next Steps

• Host conference call on July 30, 2026, at 4:30 p.m. ET to discuss Q2 2026 results and provide an operational update.
• Continue to focus on innovation and disciplined operational execution.
• Grow at the high end of the MedTech industry.

Key Dates

Recommendation

While the Q2 results are strong and management expresses confidence, the narrowing of guidance and the inherent risks in the MedTech industry (cybersecurity, regulatory, economic) warrant a cautious 'hold' recommendation. Investors should monitor the integration of new structures and the ongoing recovery from the cyber incident.

Keywords

Medical Technologies, MedSurg, Neurotechnology, Orthopaedics, Medical Devices, Healthcare, Sales Growth, Earnings Per Share